Frontiers
US$ 23.28
glp 1 gip glucagon triple agonist Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor TrimRX | GLP-1 vs GIP:
Description
Note: Participants in the STEP-1 trial were patients with obesity
Thus, this prompted the market growth
Cukierman-Yaffe, T
doi: 10.1016/j.coph.2017.03.006 42 PackerMAnkerSDButlerJFilippatosGZannadF
While 12% of adults in the US have used GLP-1s, only 1% of eligible patients have received bariatric surgery
Therefore, anyone using GLP-1s should require oversight of nutrition: adequate protein, micronutrients, healthy fats, fiber, and perhaps supplementation/support as needed
